Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

(2018) Lanping Xu et al.   Journal of Hematology & Oncology

Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease

(2018) Xingxing Yu et al.   Science China-Life Sciences

Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children

(2018) Wenjing Yu et al.   Science China-Life Sciences

The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China

(2018) Yu Wang et al.   CANCER LETTERS

Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission

(2018) Yang Liu et al.   Science China-Life Sciences

Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes

(2017) Yu Wang et al.   OncoImmunology

Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen–Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies

(2016) Elad Jacoby et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen–Matched Related or Unrelated Donor

(2016) Didier Blaise et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States

(2016) Jane Apperley et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index

(2016) Asad Bashey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

(2016) M. Mielcarek et al.   BLOOD

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

(2016) Rohtesh S. Mehta et al.   BRITISH JOURNAL OF HAEMATOLOGY

Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study

(2016) Y. Wang et al.   CLINICAL CANCER RESEARCH

Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplant

(2016) Annalisa Ruggeri et al.   HAEMATOLOGICA

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

(2016) Shannon R. McCurdy et al.   HAEMATOLOGICA

Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT

(2016) Marie T. Rubio et al.   Journal of Hematology & Oncology

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

(2016) Irwin Walker et al.   LANCET ONCOLOGY

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

(2016) Nicolaus Kröger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide

(2016) Tara M. Robinson et al.   SEMINARS IN HEMATOLOGY

Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplant

(2016) Annalisa Ruggeri et al.   HAEMATOLOGICA

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

(2016) Shannon R. McCurdy et al.   HAEMATOLOGICA

An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide

(2015) Munira Shabbir-Moosajee et al.   AMERICAN JOURNAL OF HEMATOLOGY

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells

(2015) Nicoletta Cieri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

(2015) S. R. McCurdy et al.   BLOOD

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

(2015) S. O. Ciurea et al.   BLOOD

HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide

(2015) E J Fuchs   BONE MARROW TRANSPLANTATION

Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update

(2015) A Bacigalupo et al.   BONE MARROW TRANSPLANTATION

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

(2015) Yvette L. Kasamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Haploidentical transplantation: the search for the best donor

(2014) R. Handgretinger   BLOOD

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

(2014) P. Armand et al.   BLOOD

Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers

(2014) Y-J Chang et al.   BONE MARROW TRANSPLANTATION

Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

(2014) Christopher G. Kanakry et al.   JOURNAL OF CLINICAL ONCOLOGY

T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation

(2013) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

(2010) L. Luznik et al.   BLOOD

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

(2009) Jürgen Finke et al.   LANCET ONCOLOGY